m+Medelevator.RU
← Поиск публикаций
Journal of thermal biology · 2026

Sequential cryoablation enhances chemotherapeutic efficacy in pancreatic cancer by downregulating TGF-β mediated fibrosis in the sub-lethal zone.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cao Yukun, Li Xin, Gong Wangang, Tan Jia, Shen Jing, Zhou Xinli

Аннотация

Cryoablation is effective for solid tumors but is often constrained by limited thermal efficiency and incomplete ablation. Conventional strategies prioritize expanding lethal isotherms to minimize the sub-lethal zone, a practice that increases the risk of collateral injury to adjacent critical structures. This study proposes a novel strategy utilizing the sub-lethal zone to remodel the tumor microenvironment for enhanced therapeutic efficacy. Using pancreatic cancer and stellate cell co-cultured spheroids and subcutaneous tumor models, we investigated fibrotic tumor microenvironment changes induced by the cryoablation sub-lethal zone combined with gemcitabine plus nab-paclitaxel. Results demonstrated that cryoablation significantly disrupted collagen structures and downregulated TGF-β1, p-Smad3, α-SMA, and Collagen I expression. This modulation is associated with the mitigation of fibrotic barriers, thereby potentially improving the accessibility of chemotherapy drugs within the sub-lethal zone. In vivo, cryoablation followed by chemotherapy yielded optimal efficacy compared to reverse sequencing or monotherapy, significantly inhibiting angiogenesis and promoting mitochondrial apoptosis via upregulated Bax and Caspase-3 levels. In conclusion, cryoablation functions as a potent tumor microenvironment remodeler. By downregulating TGF-β/Smad signaling, it sensitizes pancreatic ductal adenocarcinoma to subsequent chemotherapy, offering a superior sequential strategy to effectively inhibit the growth of residual tumor cells, offering an approach to improve local tumor control in PDAC.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты